Malignant disease and immunosuppression
On this page you will find our recommendations sorted by BNF chapter.
Appraisal Reports are available to stakeholders on request.
Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on firstname.lastname@example.org
|Rituximab for the treatment of Immune (Idiopathic) Thrombocytopenic Purpura (ITP) in adults and children (unlicensed indication)||Recommendation||Recommended as a second line option||09/04/2015|